CoChat

Creatine for neuroprotection in neurodegenerative disease: end of story?

Bender, Andreas, Klopstock, Thomas · 2016 · Amino Acids

The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.

Abstract

Creatine (Cr) is a natural compound that plays an important role in cellular energy homeostasis. In addition, it ameliorates oxidative stress, glutamatergic excitotoxicity, and apoptosis in vitro as well as in vivo. Since these pathomechanisms are implicated to play a role in several neurodegenerative diseases, Cr supplementation as a neuroprotective strategy has received a lot of attention with several positive animal studies in models of Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). This has led to a number of randomized clinical trials (RCT) with oral Cr supplementation, with durations up to 5 years. In this paper, we review the evidence and consequences stemming from these trials. In the case of PD, the initial phase II RCT was promising and led to a large and well-designed phase III trial, which, however, turned out to be negative for all outcome measures. None of the RCTs that have examined effects of Cr in ALS patients showed any clinical benefit. In HD, Cr in high doses (up to 30 g/day) was shown to slow down brain atrophy in premanifest Huntingtin mutation carriers. In spite of this, proof is still lacking that Cr can also have beneficial clinical effects in this group of patients, who will go on to develop HD symptoms. Taken together, the use of Cr supplementation has so far proved disappointing in clinical studies with a number of symptomatic neurodegenerative diseases.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00726-015-2165-0

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 74 references

Research works printed but not linked: 3

  1. National Academies of Sciences, Engineering, and Medicine (2015) Reproducibility issues in research with animals and animal models: workshop in Brief. The National Academies Press, Washington, DC, 1–8. ISBN 978-0-309-38017-1
  2. Tabrizi SJ, Cleeter MW, Xuereb J, Taanman JW, Cooper JM, Schapira AH (1999) Biochemical abnormalities and excitotoxicity in Huntington’s disease brain. Ann Neurol 45(1):25–32 · doi:10.1002/1531-8249(199901)45:1<25::aid-art6>3.0.co;2-e
  3. Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, Beal MF (2009) Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s diseases. J Neurochem 109(5):1427–1439. doi: 10.1111/j.1471-4159.2009.06074.x · DOI · Paper page

Cited by

See all 96

Metadata

Authors
Bender, A., & Klopstock, T.
Affiliations
  • Therapiezentrum Burgau (DE)
  • German Center for Neurodegenerative Diseases (DE)
Corresponding author
Bender, Andreas
Venue
Amino Acids
Published
2016-01-09
Volume
48
Issue
8
Pages
1929-1940
ISSN
  • 0939-4451 (ISSN-L)
  • 1438-2199
OpenAlex
W2231841779
Cited by
96
References
73
Citations by year
2026: 8 · 2025: 10 · 2024: 7 · 2023: 9 · 2022: 9 · 2021: 9 · 2020: 12 · 2019: 12 · 2018: 6 · 2017: 7 · 2016: 7
FWCI
1.48
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Amino Acids (publishedVersion)
  • PubMed (publishedVersion)
  • DZNE Pub (submittedVersion)
  • OPUS (Augsburg University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
  • Health Sciences › Medicine › Physiology (medical) › Biochemical effects in animals
Keywords
creatine supplementation, neuroprotection, neurodegenerative diseases, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, oxidative stress, glutamate excitotoxicity, apoptosis, brain atrophy, clinical trial results, energy homeostasis
MeSH terms
Animals, Creatine, Disease Models, Animal, Dose-Response Relationship, Drug, Humans, Randomized Controlled Trials as Topic, Neuroprotective Agents, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Creatine for neuroprotection in neurodegenerative disease: end of story? https://app.cochat.ai/papers/10.1007/s00726-015-2165-0
The paper
Bender, A., & Klopstock, T. (2016). Creatine for neuroprotection in neurodegenerative disease: end of story? Amino Acids. https://doi.org/10.1007/s00726-015-2165-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.